| Glomerular hyperfiltration in diabetes: mechanisms, clinical significance, and treatment L Tonneijck, MHA Muskiet, MM Smits, EJ Van Bommel, HJL Heerspink, ... Journal of the American Society of Nephrology 28 (4), 1023-1039, 2017 | 733 | 2017 |
| The renal hemodynamic effects of the SGLT2 inhibitor dapagliflozin are caused by post-glomerular vasodilatation rather than pre-glomerular vasoconstriction in metformin-treated … EJM van Bommel, MHA Muskiet, MJB van Baar, L Tonneijck, MM Smits, ... Kidney international 97 (1), 202-212, 2020 | 271 | 2020 |
| SGLT2 inhibition in the diabetic kidney—from mechanisms to clinical outcome EJM van Bommel, MHA Muskiet, L Tonneijck, MHH Kramer, M Nieuwdorp, ... Clinical Journal of the American Society of Nephrology 12 (4), 700-710, 2017 | 247 | 2017 |
| Combined NOX1/4 inhibition with GKT137831 in mice provides dose-dependent reno-and atheroprotection even in established micro-and macrovascular disease SP Gray, JC Jha, K Kennedy, E Van Bommel, P Chew, C Szyndralewiez, ... Diabetologia 60, 927-937, 2017 | 114 | 2017 |
| Understanding Empa-Reg outcome MHA Muskiet, DH van Raalte, EJM van Bommel, MM Smits, L Tonneijck The lancet Diabetes & endocrinology 3 (12), 928-929, 2015 | 89 | 2015 |
| Effects of 12-week treatment with dapagliflozin and gliclazide on faecal microbiome: Results of a double-blind randomized trial in patients with type 2 diabetes EJM van Bommel, H Herrema, M Davids, MHH Kramer, M Nieuwdorp, ... Diabetes & metabolism 46 (2), 164-168, 2020 | 53 | 2020 |
| SGLT2 inhibition and uric acid excretion in patients with type 2 diabetes and normal kidney function DLS Suijk, MJB van Baar, EJM van Bommel, Z Iqbal, MM Krebber, ... Clinical Journal of the American Society of Nephrology 17 (5), 663-671, 2022 | 48 | 2022 |
| Renal hemodynamic effects of sodium-glucose cotransporter 2 inhibitors in hyperfiltering people with type 1 diabetes and people with type 2 diabetes and normal kidney function EJM van Bommel, Y Lytvyn, BA Perkins, N Soleymanlou, NM Fagan, ... Kidney international 97 (4), 631-635, 2020 | 44 | 2020 |
| Antihypertensive effects of SGLT2 inhibitors in type 2 diabetes MHA Muskiet, EJM van Bommel, DH van Raalte The lancet Diabetes & endocrinology 4 (3), 188-189, 2016 | 38 | 2016 |
| Effects of dapagliflozin and gliclazide on the cardiorenal axis in people with type 2 diabetes EJM van Bommel, MM Smits, D Ruiter, MHA Muskiet, MHH Kramer, ... Journal of hypertension 38 (9), 1811-1819, 2020 | 29 | 2020 |
| SGLT2 inhibition versus sulfonylurea treatment effects on electrolyte and acid–base balance: secondary analysis of a clinical trial reaching glycemic equipoise: tubular effects … EJM van Bommel, F Geurts, MHA Muskiet, A Post, SJL Bakker, ... Clinical Science 134 (23), 3107-3118, 2020 | 21 | 2020 |
| The osteoblast: Linking glucocorticoid-induced osteoporosis and hyperglycaemia? A post-hoc analysis of a randomised clinical trial EJM van Bommel, RT de Jongh, M Brands, AC Heijboer, M den Heijer, ... Bone 112, 173-176, 2018 | 19 | 2018 |
| Insulin sensitivity and renal hemodynamic function in metformin-treated adults with type 2 diabetes and preserved renal function EJM van Bommel, D Ruiter, MHA Muskiet, MJB van Baar, MHH Kramer, ... Diabetes Care 43 (1), 228-234, 2020 | 18 | 2020 |
| The effect of dapagliflozin on apolipoprotein B and glucose fluxes in patients with type 2 diabetes and well‐controlled plasma LDL cholesterol KEC Bouter, EJM van Bommel, H Jansen, D van Harskamp, H Schierbeek, ... Diabetes, Obesity and Metabolism 22 (6), 988-996, 2020 | 15 | 2020 |
| Renoprotection in LEADER and EMPA-REG OUTCOME MHA Muskiet, L Tonneijck, EJM van Bommel, MM Smits, DH van Raalte The Lancet Diabetes & Endocrinology 4 (10), 812-814, 2016 | 15 | 2016 |
| 243-OR: ADA Presidents' Select Abstract: Dapagliflozin Reduces Measured GFR by Reducing Renal Efferent Arteriolar Resistance in Type 2 Diabetes EJ van Bommel, MA Muskiet, B VAN, M JACOBUS, MH KRAMER, ... Diabetes 68 (Supplement_1), 2019 | 9 | 2019 |
| Kidney hemodynamic profile and systemic vascular function in adults with type 2 diabetes: analysis of three clinical trials AC Hesp, MM Smits, EJM van Bommel, MHA Muskiet, L Tonneijck, ... Journal of Diabetes and its Complications 36 (3), 108127, 2022 | 3 | 2022 |
| Glucosuria interferes with measurement of effective renal plasma flow using para-aminohippuric acid, with a focus on SGLT2 inhibitors RA Scholtes, ITN Nguyen, EJM van Bommel, N Willekes, ... Kidney International Reports 5 (11), 2052-2054, 2020 | 3 | 2020 |
| Kidney hemodynamic function in men and postmenopausal women with type 2 diabetes and preserved kidney function DM van Velzen, MM Smits, EJM van Bommel, MHA Muskiet, L Tonneijck, ... American Journal of Physiology-Renal Physiology 320 (6), F1152-F1158, 2021 | 2 | 2021 |
| Exposure–Response Analysis of the Sodium–Glucose Cotransporter-2 Inhibitors Dapagliflozin and Empagliflozin on Kidney Hemodynamics in Patients with Type 2 Diabetes S van der Hoek, JV Koomen, EJM van Bommel, CM Mosterd, RA Scholtes, ... Journal of personalized medicine 13 (5), 747, 2023 | 1 | 2023 |
